Hot stock: Workers clean the windows of a building of Roche in Rotkreuz. Sales of Roche’s Covid-19 tests have helped boost its stock in 2020. — Reuters
THE timing was precise, the choreography immaculate: with two deft maneuvres, a new generation of the Oeri-Hoffmann family marked its growing influence over the wealthiest dynasty in Switzerland.
First, seven members of the fifth generation late last year joined the clan’s shareholder pool, which oversees a US$25bil stake in pharmaceuticals giant Roche Holding AG. Then, in March, another member of that generation, Joerg Duschmale, replaced his uncle on the drugmaker’s board.
Already a subscriber? Log in.
Subscribe now for a chance to win your dream holiday!
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
